12 results about "Graft rejections" patented technology

The present invention relates to interleukin-2 variants, to pharmaceutical compositions comprising said interleukin-2 variants, in a pharmaceutically acceptable carrier, and to their implementation in the prevention or treatment of cancer, or in the prevention or treatment of a disease selected from the group consisting of acute or chronic inflammatory diseases, allergic diseases, autoimmune diseases, graft-versus-host disease and graft rejection.

The invention relates to Interleukin-2 (IL-2) variants for the prevention or treatment of immune disorders, including with no limitations allergic, autoimmune, chronic or acute inflammatory and infectious diseases; graft-versus-host disease; graft rejection and cancer. The invention also relates to the use of said IL-2 variants for the screening of anti-IL-2 antibodies with pro-T-effector or pro-T-regulatory cell activity.

This invention discloses the role of the POFUT1 gene in determining the function of tissue-infiltrating CD4+ T cells and the application of related biomarkers in diseases, belonging to the field of biomedical technology. This invention discovers that POFUT1 is a decisive gene regulating the development of CXCR5+CD4 T cells; simultaneously, CXCR5+ and SLAMF1+CD4 T cells, as tissue-infiltrating source cells, possess the function of carrying out CD4 T cell-mediated antigen-specific killing and tissue destruction, leading to the pathogenesis of autoimmune diseases. Related applications include: using the POFUT1 gene, CXCR5+, and SLAMF1+CD4 T cells as biomarkers for the clinical diagnosis and treatment of diseases caused by tissue-infiltrating CD4 T cells, such as autoimmune diseases and xenotransplant rejection. The killing function of CXCR5+ and SLAMF1+CD4 T cells as tissue-infiltrating source cells can also be used to treat tumors.

Described herein are kits, compositions, and methods for detecting porcine antigens in a biological sample. The kit comprises a support, an anti-porcine antibody coupled to the support, and instructions for preparing a lysate from a porcine donor source and contacting the lysate with the anti-porcine antibody. The kit can be used to determine the risk of graft rejection in a human subject accepting or considering graft from a porcine donor.

The application provides an anti-CD3 monoclonal antibody, a bispecific antibody and application thereof, and particularly provides an antibody or antigen binding fragment, which comprises CDRs selected from at least one of the following: heavy chain variable region CDRs of SEQ ID NO: 1-3 or a conservatively modified form thereof; light chain variable region CDRs of SEQ ID NO: 4-6 or a conservatively modified form thereof. The antibody or antigen binding fragment has different affinities to CD3 proteins in different pHs, has weak binding capacity in normal pH animal tissues or peripheral blood, has low peripheral drug concentration, reduces the risk of off-target toxicity, has strong affinity to CD3 in tumor tissues or the periphery thereof, is beneficial to the distribution of the antibody to the tumor local part, increases the local drug concentration, and the bispecific antibody prepared from the antibody can promote the combination of T cells and tumor cells, has high safety and specificity, and can effectively treat tumors, autoimmune diseases, inflammatory diseases and / or transplant rejection.

The disclosure provides a method for treating and / or preventing graft rejection with A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, member-13 (ADAMT S13). The disclosure provides a method for increasing ADAMTS13-mediated von Willebrand factor (VWF) cleavage in a subject that received a graft by administering ADAMTS13. The disclosure also provides a method of determining the likelihood that a subject will rejection a graft.

The present disclosure relates to methods of treating or reducing the risk of transplant rejection or increasing a duration of time before transplant rejection occurs in a subject in need thereof (e.g., a human) by administering an antagonist that targets CD40 or CD154, such as an anti-CD40 antibody or an antigen-binding fragment thereof (e.g., a humanized anti-CD40 antibody or antigen-binding fragment thereof. The transplant may be an allogeneic or xenogeneic transplant (e.g., a cell, tissue, or organ or portion thereof).

Disclosed are PD-L1 presenting compositions. The compositions may be used to effect immunomodulation in a variety of contexts. The compositions may be used to decrease rates of transplant rejection, including pancreatic islet cell transplantation. The compositions are useful for the treatment of type 1 diabetes.

The invention discloses an oxazolopyridine compound as well as a preparation method and medical application thereof. The structure of the compound is shown as a formula (I), the oxazolopyridine compound or the pharmaceutically acceptable salt, tautomer, meracemate, raceme, stereoisomer, metabolite, metabolic precursor, prodrug or solvate of the oxazolopyridine compound can be applied to the preparation of PD-L1 inhibitors, such as PD-L1 inhibitors, PD-L1 inhibitors, PD-L1 inhibitors, PD-L1 inhibitors, PD-L1 inhibitors, PD-L1 inhibitors, PD-L1 inhibitors, PD-L1 inhibitors, PD-L1 inhibitors and PD-L1 inhibitors. The compound is applied to preparation of immunomodulator drugs for preventing or treating tumors, autoimmune diseases, organ transplant rejection, infectious diseases and inflammatory diseases.

The present invention provides an in vitro method for obtaining and purifying regulatory T cells from thymic tissue (or thyTreg cells), which makes it possible to obtain more than 10 billion cells from a single thymus. These thyTregs obtained in the invention have a purity of more than 95% and very high suppressive capacity, survival and viability, in addition to being safe from a clinical viewpoint. The foregoing would not require the use of massive ex vivo cell expansion protocols. The transfer of these thyTreg cells to patients enables immune tolerance induction. Thus, said cells may be used as cell therapy to induce immune tolerance in the treatment and / or prevention of transplant rejections and in autoimmune diseases.

The present invention relates to interleukin-2 variants, to pharmaceutical compositions comprising said interleukin-2 variants, in a pharmaceutically acceptable carrier, and to their implementation in the prevention or treatment of cancer, or in the prevention or treatment of a disease selected from the group consisting of acute or chronic inflammatory diseases, allergic diseases, autoimmune diseases, graft-versus-host disease and graft rejection.

The present disclosure relates to vectors, such as DNA plasmids, comprising multiple nucleic acid sequences of interest engineered to be co-expressed as separate molecules, pharmaceutical compositions comprising such vectors and the use of such vectors and such pharmaceutical compositions in the treatment or prevention of diseases or in the prophylactic or therapeutic treatment of autoimmune diseases, allergic diseases and graft rejection.